Part 4, Reference for Chapter 48: Adamantiades–Behçet disease
Skip chapter table of contents and go to main content
- 1 Complex aphthosis and Behçet's disease. Dermatol Clin 2003;21:418. , , .
- 2 Behçet's disease. Clin Exp Med 2004;4:10–20. Cross Ref link Pubmed link , .
- 3 Epidemiology of Adamantiades–Behçet's disease. In: Zierhut M, Ohno S, eds. Immunology of Behçet's Disease. Lisse: Swets and Zeitlinger, 2003:1–16. .
- 4 Epidemiology and clinical manifestations of Adamantiades–Behçet disease in Germany – current pathogenetic concepts and therapeutic possibilities. J Dtsch Dermatol Ges 2006;4:49–66. Cross Ref link Pubmed link , , , et al.
- 5 Changing clinical expression of Behçet disease in Korea during three decades (1983–2012): chronological analysis of 3674 hospital‐based patients. Br J Dermatol 2014;170:458–61. Cross Ref link Pubmed link , , , et al.
- 6 Pathogenesis of Adamantiades–Behçet's disease. Med Microbiol Immunol 2003;192:149–55. Cross Ref link Pubmed link , .
- 7 Behçet's disease. Arthritis Res Ther 2003;5:139–46. Cross Ref link Pubmed link , .
- 8 Mucocutaneous criteria for the diagnosis of Behçet's disease: an analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol 1995;32:968–76. Cross Ref link Pubmed link , , , et al.
- 9 The role of infectious agents in the pathogenesis of Behçet's disease. Adv Exp Med Biol 2003;528:181–3. Cross Ref link Pubmed link , , , et al.
- 10 Streptococcus sanguinis and the sera of patients with Behçet's disease stimulate membrane expression of α‐enolase in human dermal microvascular endothelial cells. Arch Dermatol Res 2013;305:223–32. Cross Ref link Pubmed link , , , et al.
- 11 High seroprevalence of anti‐Mycoplasma fermentans antibodies in patients with malignant aphthosis. J Invest Dermatol 2003;121:211–12. Cross Ref link Pubmed link , , .
- 12 Higher expression of Toll‐like receptors 2, 3, 4, and 8 in ocular Behcet's disease. Invest Ophthalmol Vis Sci 2013;54:6012–17. Cross Ref link Pubmed link , , , et al.
- 13 HLA‐B51/B5 and the risk of Behçet's disease: a systematic review and meta‐analysis of case‐control genetic association studies. Arthritis Rheum 2009;61:1287–96. Cross Ref link Pubmed link , , , et al.
- 14 Univariate and multivariate analyses comparing demographic, genetic, clinical, and serological risk factors for severe Adamantiades–Behçet's disease. Adv Exp Med Biol 2003;528:123–6. Cross Ref link Pubmed link , , .
- 15 Behçet's disease: familial clustering and immunogenetics. Clin Exp Rheumatol 2005;23(Suppl. 38):S96–105. Pubmed link .
- 16 The genetics of Adamantiades–Behcet's disease. Semin Ophthalmol 2008;23:73–9. Cross Ref link Pubmed link , .
- 17 Immunology and functional genomics of Behçet's disease. Cell Mol Life Sci 2003;60:1903–22. Cross Ref link Pubmed link , , , et al.
- 18 Genome‐wide association study identifies variants in the MHC class I, IL10, and IL23R‐IL12RB2 regions associated with Behçet's disease. Nat Genet 2010;42:698–702. Cross Ref link Pubmed link , , , et al.
- 19 2010:163. , , , et al. HLA‐antigens and their importance as prognostic‐marker in Adamantiades–Behçet's disease (ABD) – is HLA‐Bw4 a new prognostic marker? Abstracts of the 14th International Conference on Behçet's disease, London,
- 20 Behçet's disease (Adamantiades syndrome). Oral Dis 2006;12:78–84. Cross Ref link Pubmed link , , .
- 21 Genome‐wide association studies identify IL23R‐IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 2010;42:703–6. Cross Ref link Pubmed link , , , et al.
- 22 Haplotype association of IL‐8 gene with Behcet's disease. Tissue Antigens 2007;69:128–32. Cross Ref link Pubmed link , , , et al.
- 23 IL‐23R gene confers susceptibility to Behcet's disease in a Chinese Han population. Ann Rheum Dis 2010;69:1325–8. Cross Ref link Pubmed link , , , et al.
- 24 Behçet's syndrome: a critical digest of the 2012–2013 literature. Clin Exp Rheumatol 2013;31(Suppl. 77):108–17. Pubmed link , , , et al.
- 25 Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005;4:81–3. Cross Ref link Pubmed link .
- 26 Role of IL‐12B promoter polymorphism in Adamantiades–Behçet's disease susceptibility: an involvement of Th1 immunoreactivity against streptococcus sangunis antigen. J Invest Dermatol 2006;126:1534–40. Cross Ref link Pubmed link , , , et al.
- 27 Diversity of γδ T cells in patients with Behçet's disease is indicative of polyclonal activation. Oral Dis 2006;12:271–7. Cross Ref link Pubmed link , , , et al.
- 28 Alpha tropomyosin as a self‐antigen in patients with Behçet's disease. Clin Exp Immunol 2005;140:368–75. Cross Ref link Pubmed link , , , et al.
- 29 Identification of kinectin as a novel Behçet's disease autoantigen. Arthritis Res Ther 2005;7:R1133–9. Cross Ref link Pubmed link , , , et al.
- 30 The role of heat shock proteins in Behçet's disease. Clin Exp Rheumatol 2003;21:S44–8. Pubmed link , .
- 31 Serum levels of free heat shock protein 70 and anti‐HSP70 are elevated in Behçet's disease. Clin Exp Rheumatol 2008;26(Suppl. 50):S96–8. Pubmed link , , , et al.
- 32 Adamantiades–Behçet's disease: serum IL‐8 is a more reliable marker for disease activity than c‐reactive protein and erythrocyte sedimentation rate. Dermatology 2000;201:37–9. Cross Ref link Pubmed link , , , et al.
- 33 Significance of serum interleukin‐8 levels in patients with Behcet's disease: high levels may indicate vascular involvement. Int J Dermatol 2009;48:259–64. Cross Ref link Pubmed link , , , et al.
- 34 Classifying patients with Behçet's disease for disease severity, using a discriminating analysis method. Clin Exp Dermatol 2009;34:151–5. Cross Ref link Pubmed link , , , et al.
- 35 Upregulated IL‐23 and IL‐17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 2008;49:3058–64. Cross Ref link Pubmed link , , , et al.
- 36 Raised concentration of soluble form of vascular endothelial cadherin and IL‐23 in sera of patients with Behçet's disease. Mod Rheumatol 2010;20:154–9. Cross Ref link Pubmed link , , .
- 37 Up‐regulation of Th17 and related cytokines in Behçet's disease corresponding to disease activity. Clin Exp Rheumatol 2013;31(Suppl. 77):32–40. Pubmed link , , , et al.
- 38 Increased expression of IL‐22 is associated with disease activity in Behcet's disease. PLOS One 2013;8:e59009. Cross Ref link Pubmed link , , , et al.
- 39 Role of IL‐22‐ and TNF‐α‐producing Th22 cells in uveitis patients with Behçet's disease. J Immunol 2013;190:5799–808. Cross Ref link Pubmed link , , , et al.
- 40 Serum level of interleukin‐33 and soluble ST2 and their association with disease activity in patients with Behcet's disease. J Korean Med Sci 2013;28:1145–53. Cross Ref link Pubmed link , , , et al.
- 41 An update on Behçet's disease. J Eur Acad Dermatol Venereol 2007;21:1–10. Cross Ref link Pubmed link , .
- 42 Human alpha‐enolase from endothelial cells as a target antigen of anti‐endothelial cell antibody in Behçet's disease. Arthritis Rheum 2003;48:2025–35. Cross Ref link Pubmed link , , , et al.
- 43 A historical review of early descriptions of Adamantiades–Behçet's disease. J Invest Dermatol 2002;119:201–5. Cross Ref link Pubmed link , .
- 44 International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078–80. Pubmed link
- 45 1999. , , , et al. Behçet's Disease and Diseases for its Differential Diagnosis in Dermatology. Annual Report of the Behçet's Disease Research Committee of Japan. Tokyo: Behçet's Disease Research Committee of Japan,
- 46 International Team for the Revision of the International Criteria for Behçet's Disease (ITR‐ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2013;28:338–47. Pubmed link
- 47 Comparison of the clinical features of recurrent aphthous stomatitis and Behçet's disease. Clin Exp Dermatol 2009;34:e208–12. Cross Ref link Pubmed link , , , et al.
- 48 Morbus Adamantiades–Behcet. Ophthalmologe 2005;102:329–34. Cross Ref link Pubmed link .
- 49 Pseudo‐Behçet's disease. Dermatol Clin 2003;21:49–61. Cross Ref link Pubmed link .
- 50 Current epidemiological data from the German Registry of Adamantiades–Behçet's disease. Adv Exp Med Biol 2003;528:43–8. Cross Ref link Pubmed link , , , et al.
- 51 Prognostic factors of vision in patients with Behçet disease. Ophthalmology 1995;102:317–21. Cross Ref link Pubmed link , , , et al.
- 52 Are erythema nodosum‐like lesions and superficial thrombophlebitis prodromal in terms of visceral involvement in Behçet's disease? Int J Clin Pract 2005;59:69–71. Cross Ref link Pubmed link , , .
- 53 Comparison of presenting features and three‐year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm 2012;20:423–8. Cross Ref link Pubmed link , , , et al.
- 54 Current concepts in the treatment of Adamantiades–Behçet's disease. Drugs Fut 2009;34:749–63. Cross Ref link , , , et al.
- 55 Adamantiades–Behçet's disease. In: Katsambas AD, Lotti TM, eds. European Handbook of Dermatological Treatments, 2nd edn. Berlin: Springer, 2003:16–26. Cross Ref link .
- 56 New evidence‐based treatment approach in Behçet's disease. Pathol Res Intern 2012;2012:871019. .
- 57 Practical aspects of management of recurrent aphthous stomatitis. J Eur Acad Dermatol Venereol 2007;21:1019–26. Cross Ref link Pubmed link , , , et al.
- 58 The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: comparison between recurrent aphthous ulcers and the oral ulcers of Behçet's disease. J Eur Acad Dermatol Venereol 2008;22:590–5. Cross Ref link Pubmed link , , .
- 59 Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet's disease. Graefes Arch Clin Exp Ophthalmol 2007;245:451–6. Cross Ref link Pubmed link , , .
- 60 Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease. J Ocul Pharmacol Ther 2007;23:395–401. Cross Ref link Pubmed link , , , et al.
- 61 Klinik und Therapie chronisch rezidivierender Aphthen. Hautarzt 2012;63:693–703. Cross Ref link Pubmed link , , , et al.
- 62 New approaches in the treatment of Adamantiades–Behçet's disease. Curr Opin Rheumatol 2006;18:3–9. Cross Ref link Pubmed link , , , et al.
- 63 Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence‐based recommendations for the management of Behçet disease. Ann Rheum Dis 2009;68:1528–34. Cross Ref link Pubmed link , , , et al.
- 64 Traitement de la maladie de Behçet. Rev méd interne 2014;35126–38. , , , et al.
- 65 A double‐blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology (Oxford) 2006;45:348–52. Cross Ref link Pubmed link , , , et al.
- 66 Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double‐blind, placebo‐controlled study. Drugs R D 2003;4:19–28. Cross Ref link Pubmed link , , , et al.
- 67 Colchicine versus placebo in Behçet's disease: randomized, double‐blind, controlled crossover trial. Mod Rheumatol 2009;19:542–9. Cross Ref link Pubmed link , , , et al.
- 68 A double blind study of colchicine in Behcet's disease. Haematologica 1980;65:399–402. Pubmed link , , , et al.
- 69 A double‐blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001;44:2686–92. Cross Ref link Pubmed link , , , et al.
- 70 Colchicine in Behcet syndrome: a longterm survey of patients in a controlled trial. J Rheumatol 2014;41:735–8. Cross Ref link Pubmed link , , , et al.
- 71 Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Dermatology 1996;192:125–8. Cross Ref link Pubmed link , , , et al.
- 72 Colchicine and benzathine penicillin in the treatment of Behçet disease: a case comparative study. Dermatology Online J 2005;11(3):3. , , , et al.
- 73 Oral zinc sulfate in the treatment of Behçet's disease: a double blind cross‐over study. J Dermatol 2006;33:541–6. Cross Ref link Pubmed link , , , et al.
- 74 Dapsone in Behçet's disease: a double‐blind, placebo‐controlled, cross‐over study. J Dermatol 2002;29:267–79. Cross Ref link Pubmed link , , .
- 75 A controlled trial of azathioprine in Behçet's disease. N Engl J Med 1990;322:281–5. Cross Ref link Pubmed link , , , et al.
- 76 Interferon alfa‐2a in the treatment of Behçet's disease: a randomized placebo‐controlled and double‐blind study. Arch Dermatol 2002;138:467–71. Cross Ref link Pubmed link , , , et al.
- 77 Low‐dose natural human interferon‐alpha lozenges in the treatment of Behçet's syndrome. Rheumatology (Oxford) 2009;48:1388–91. Cross Ref link Pubmed link , , , et al.
- 78 Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double‐blind, placebo‐controlled trial. Ann Intern Med 1998;128:443–50. Cross Ref link Pubmed link , , , et al.
- 79 Double‐masked trial of cyclosporin versus colchicine and long‐term open study of cyclosporin in Behçet's disease. Lancet 1989;1(8647):1093–6. Cross Ref link Pubmed link , , , et al.
- 80 Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc 1988;20(Suppl. 4):136–43. Pubmed link , , , et al.
- 81 Effect of cyclosporine A on the hearing loss in Behçet's disease. Ann Otol Rhinol Laryngol 1991;100464–8. , , , et al.
- 82 Low‐dose cyclosporin in Behçet's disease: follow‐up controlled study with emphasis on extraocular manifestations and neuro‐Behçet's disease. In: O'Duffy JD, Kokmen E, eds. Behçet's Disease: Basic and Clinical Aspects. New York: Marcel Dekker, 1991:603–12. .
- 83 Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol 1992;76:241–3. Cross Ref link Pubmed link , , , et al.
- 84 Pulse cyclophosphamide (PCP) for ocular lesions of Behçet's disease: double blind crossover study. Arthritis Rheum 1999;42:S320. , , , et al.
- 85 Short‐term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98–105. Pubmed link , , , et al.
- 86 Rituximab in intractable ocular lesions of Behçet's disease; randomized single‐blind control study (pilot study). Int J Rheum Dis 2010;13:246–52. Cross Ref link Pubmed link , , , et al.
- 87 Treatment with acyclovir does not affect orogenital ulcers in Behcet's syndrome: a randomized double‐blind trial. Br J Rheumatol 1998;27:300–2. Cross Ref link , , .
- 88 Inefficacy of azapropazone in the acute arthritis of Behcet's syndrome: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol 1995;13:493–5. Pubmed link , , , et al.
- 89 A double‐masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm 2007;15:63–70. Cross Ref link Pubmed link , , , et al.
- 90 Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease: an open‐label, single‐centre study. Drugs R D 2008;9:455–9. Cross Ref link Pubmed link , , , et al.
- 91 Morbus Adamantiades–Behçet. In: Mrowietz U, ed. Ciclosporin in der Dermatologie. Stuttgart: Thieme, 2003:38–51. .
- 92 Thalidomide for treatment of intestinal involvement of juvenile‐onset Behçet disease. Inflamm Bowel Dis 2008;14:396–400. Cross Ref link Pubmed link , , , et al.
- 93 Treatment of Adamantiades–Behçet's disease with systemic interferon alfa. Arch Dermatol 1998;134:1010–16. Cross Ref link Pubmed link , .
- 94 Longterm visual prognosis of patients with ocular Adamantiades–Behçet's disease treated with interferon‐alpha‐2a. J Rheumatol 2008;35:896–903. Pubmed link , , , et al.
- 95 Efficacy and safety of interferon‐alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology (Oxford) 2007;46:1570–3. Cross Ref link Pubmed link , , , et al.
- 96 Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years. Int J Rheum Dis 2014;17:444–52. Cross Ref link Pubmed link , , , et al.
- 97 Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years. Int J Rheum Dis 2013;16:568–77. Cross Ref link Pubmed link , , , et al.
- 98 Anti‐TNF therapy in the management of Behçet's disease: review and basis for recommendations. Rheumatology (Oxford) 2007;46:736–41. Cross Ref link Pubmed link , , , et al.
- 99 Long‐term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24‐month follow‐up study. Rheumatology (Oxford) 2007;46:1161–4. Cross Ref link Pubmed link , , , et al.
- 100 Anti‐TNF‐alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects. Ann NY Acad Sci 2007;1110:474–84. Cross Ref link Pubmed link , , .
- 101 Infliximab for the treatment of neuro‐Behçet's disease: a case series and review of the literature. Arthritis Rheum 2008;59:285–90. Cross Ref link Pubmed link , , , et al.
- 102 Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis 2008;14:1259–64. Cross Ref link Pubmed link , , , et al.
- 103 Health‐ and vision‐related quality of life in patients receiving infliximab therapy for Behcet uveitis. Br J Ophthalmol 2013;97:338–42. Cross Ref link Pubmed link , , , et al.
- 104 Efficacy of infliximab in intestinal Behcet's disease: a Korean multicenter retrospective study. Inflamm Bowel Dis 2013;19:1833–8. Pubmed link , , , et al.
- 105 Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology 2012;51:1825–31. Cross Ref link Pubmed link , , , et al.
- 106 Interleukin‐1‐regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open‐label pilot study. Ann Rheum Dis 2012;71:563–6. Pubmed link , , , et al.